



## Lars Erik Kristensen

Country: Sweden  
Contact e-mail: larserik\_kristensen@yahoo.com  
Year of birth: 1975

### Main diplomas:

MD: 2002, Copenhagen Denmark

Rheumatologist: 2009, Lund Sweden

PhD: 2008, Lund Sweden, Anti-TNF treatment of chronic arthritis in clinical practice.

### Current position and hospital/university:

Consultant and senior researcher at Dept Rheumatology, Lund University Hospital

### Position within EULAR/international experience:

EMEUNET member

International experience: Florida State University, premed studies 1994-95

Frederiksberg University Hospital Copenhagen Denmark 2003, doctoral research

### Areas of Research/Interest:

Clinical research of efficacy and tolerability of anti-TNF treatment and other 2<sup>nd</sup> generation biologicals of chronic arthritis

### Select Publications:

1. **Kristensen LE**, Saxne T, Geborek P. Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register. *Rheumatology* dec 2008, doi:10.1093
2. **Kristensen LE**, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. *Scand J Rheumatol.* 2007 Nov-Dec;36(6):411-7.
3. **Kristensen LE**, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. *Arthritis Rheum* 2006; 54(2):600-606
4. **Kristensen LE**, Kapetanovic MC, Gülfe A, Saxne T, Söderlin MK, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established rheumatoid arthritis: Results from the South Swedish Arthritis Treatment Group Register. *Rheumatology* 2008; 47: 495-499
5. **Kristensen LE**, Gülfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register. *Ann Rheum Dis. Published Online First: 20 July 2007.* doi:10.1136/ard.2007.07354